Skeletal muscle glucose uptake in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy

Completed

• Conditions: blood cancer; chronic myeloid leukemia; 10024324; 10018424

• Registration Number: NL-OMON48288
• Lead Sponsor: Fysiologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 45

Inclusion Criteria

- Age: *18 years
- Fasting glucose level: * 6,0 mmol/l
- CML patients:
o Nilotinib treatment for at least 6 months prior to study inclusion OR
o Imatinib treatment for at least 6 months prior to study inclusion

Exclusion Criteria

- Contra-indication to exercise testing according to the ACC/AHA guidelines
- Incapable to provide informed consent
- Subgroup op patients undergoing [18F]FDG PET/CT scanning:
o Renal dysfunction with MDRD <60
o Known prior allergic reaction to [18F]FDG

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Differences in area under the glucose disappearance curve upon a single glucose<br /><br>bolus after an exercise bout. Standard uptake value (SUV) of [18F]FDG as<br /><br>determined on PET/CT images. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p> -</p><br>